Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 2/20 | 0.49 |
| ▸ | GABRA2 | P47869 | 5/20 | 0.43 |
| ▸ | GABRB2 | P47870 | 5/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
| ▸ | MMP14 | P50281 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.40 |
| ▸ | CDC7 | O00311 | 2/20 | 0.40 |
| ▸ | DBF4 | Q9UBU7 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9893835 | 0.90 | MDM2 (0.60) | MDM2GABRA2GABRB2ALDH1A1MAPT | |
| SCHEMBL9893991 | 0.88 | MDM2 (0.64) | MDM2GABRA2GABRB2MMP2MMP13 | |
| SCHEMBL1437191 | 0.87 | MDM2 (0.62) | MDM2GABRA2GABRB2ALDH1A1MAPT | |
| SCHEMBL1437622 | 0.86 | GABRA2 (0.52) | MDM2GABRA2GABRB2MAPT | |
| SCHEMBL9893880 | 0.85 | MDM2 (0.48) | MDM2GABRA2GABRB2MAPT | |
| SCHEMBL9893718 | 0.82 | MDM2 (0.45) | MDM2GABRA2GABRB2NPC1RAB9A | |
| SCHEMBL9894131 | 0.80 | MDM2 (0.46) | MDM2GABRA2GABRB2ALDH1A1MAPT | |
| SCHEMBL1437426 | 0.79 | GABRA2 (0.65) | GABRA2GABRB2NPC1RAB9A | |
| SCHEMBL1437126 | 0.78 | MDM2 (0.51) | MDM2GABRA2GABRB2ALDH1A1MAPT | |
| SCHEMBL9893706 | 0.78 | MAPT (0.45) | MDM2GABRA2GABRB2ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2470502-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | Novartis AG (CH) | 2012-07-04 | — | — | EP | disclosed |
| US-20120149661-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | NOVARTIS AG (CH) | 2012-06-14 | — | — | US | disclosed |
| WO-2011023677-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | NOVARTIS AG (CH) | 2011-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149661-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | MDM4, MDM2, TP53 | MDM2 2/4885GABRA2 4293/4885GABRB2 4278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.